Logo

Procter & Gamble to Use Osteoporosis Targets Identified by Sequenom

Dec 18, 2003

NEW YORK, Dec. 18 (Genome Web News) - Sequenom has licenced to Procter & Gamble Pharmaceuticals an undisclosed number of osteoporosis targets against which the drug company hopes to develop new therapeutics, the companies said today.

 

P&G will validate targets in osteoporosis biological and animal models to identify screening candidates. Sequenom stands to gain royalties on product sales, and is entitled to receive license and milestone payments. Sequenom will also retain all diagnostic rights to the targets.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.